VidaMed wins TUNA (transurethral needle ablation) court battle with ProSurg:

Executive Summary

A US District Court has granted VidaMed's motion for summary judgment against ProSurg for "asking, encouraging or otherwise soliciting physicians to use ProSurg's Opal and Opal Flex products to treat BPH (benign prostatic hyperplasia)." The court found that VidaMed's patent 5,536,240 covering the use of radiofrequency electrodes for treatment of BPH, known as transurethral needle ablation (TUNA), was infringed. VidaMed of Freemont, California, says the decision strengthens its case in ongoing litigation between the two companies.